Innate Pharma announces trading halt of its ordinary shares on Euronext Paris
Innate Pharma announces launch of proposed global offering and Nasdaq listing
Innate Pharma announces publication of a review article in Nature
Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress
Monalizumab to advance to Phase III in head and neck cancer
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Innate Pharma files registration statement for proposed initial public offering in the United States
Innate Pharma reports first half 2019 financial results and business update
Number of shares and voting rights of Innate Pharma as at July 17, 2019
Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
